Commodore Capital LP and Affiliates' Ownership in SAB Biotherapeutics, Inc.

Commodore Capital LP, along with its affiliates Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, filed a Schedule 13G with the SEC, disclosing their ownership in SAB Biotherapeutics, Inc. As of September 26, 2025, the group beneficially owns 4,522,977 shares of Common Stock, representing 9.9% of the outstanding shares. This ownership includes shares issued upon the conversion of Series B Convertible Preferred Stock and shares subject to a beneficial ownership limitation of 9.99%. The filing also excludes certain shares issuable upon the conversion of Series B Preferred Stock underlying enrollment and release warrants. The group certifies that the securities were not acquired for the purpose of influencing the control of the issuer.